Annual Meeting

Cracking foods’ anti-cancer properties

Intrigued first by tamarind’s antibacterial ability, researcher in Puerto Rico next sets her sights on legumes as she investigates ways to defeat triple-negative inflammatory breast cancer

What if patients with breast cancer could consume legumes, such as soy sprouts, and greatly reduce the chances of their cancer metastasizing? This is one of the questions researchers at the University of Puerto Rico at Río Piedras are interested in answering, and their work already has yielded some intriguing findings, which will be presented Tuesday in Philadelphia at the annual meeting of the American Society for Biochemistry and Molecular Biology. 

Courtesy of Keishla M. Rodríguez–Mártir
Keishla M. Rodríguez–Mártir works with her cancer cell lines.

Graduate student Keishla M. Rodríguez–Mártir is working on her dissertation in the lab of Esther Peterson–Peguero. Rodríguez–Mártir is studying coumestrol, a phytoestrogen similar in structure to estrogen and found in foods such as soy, alfalfa, clover and Kala chala (a type of chickpea), among others. She aims to determine if coumestrol has anti-cancer effects in triple-negative inflammatory breast cancer, or TN-IBC, cell lines as it does in other cancer cell lines. 

Rodríguez–Mártir’s dissertation research idea sprang from a project she was involved in as an undergraduate student at the University of Puerto Rico at Aguadilla, where she was assessing tamarind’s antibacterial properties. 

“(This property) always called my attention — how something that we can buy at the grocery store works against bacterial infections,” she said. “This was something I was interested in exploring. (I wondered if) people receiving chemotherapy could supplement their treatment with something natural and accessible to them.” 

Triple-negative breast cancer does not have estrogen or progesterone receptors, and it has low-to-no HER2 protein production. As a result, it cannot be treated with hormone or HER2-targeted therapy. 

Molecular structure of coumestrol, a phytoestrogen with a structure similar to estrogen.

The inflammatory aspect of TN-IBC further complicates clinical outcomes, because it does not present with lumps but instead creates redness and inflammation and thus may not show up on a mammogram. This presentation causes doctors to explore other possible noncancerous causes first, which ultimately delays cancer detection. By the time it is diagnosed, it usually has metastasized and consequently results in a worse prognosis for the patient. 

Rodríguez–Mártir dived into the scientific literature and came upon studies of phytoestrogens and their relationship to reduced risk of death and disease recurrence in women with breast cancer. Specifically, she focused on coumestrol because published data suggest that it has cytotoxic effects against triple-negative cell lines, but it had not been studied yet in the context of triple-negative inflammatory breast cancer. 

Rodríguez–Mártir first sought to test the hypothesis that coumestrol could have cytotoxic effects on TN-IBC cell lines by using a 2D cell-culture model of TN-IBC cells. She conducted dose-response assays with coumestrol to determine half-maximal inhibitory concentration, followed by cell viability, migration and invasion assays, complemented by assessment of downstream signaling following coumestrol treatment. 

She determined that coumestrol decreases cell viability, migration and invasion in TN-IBC cell lines. She also demonstrated that coumestrol downregulates pro-oncogenic signaling and upregulates genes involved in breast cancer suppression. 

“Studies have determined that Asian and vegetarian women with high phytoestrogen dietary consumption have a low rate of incidence of breast cancer. Further, Chinese women who have breast cancer and consume phytoestrogens have a significantly lower mortality rate than their counterparts who do not,” she said. “I would like to identify a natural compound that (patients) can easily consume to support their therapy.” 

Keishla M. Rodríguez–Mártir will present this research at 1:10 p.m. Tuesday, April 5, in Exhibit/Poster Hall A–B, Pennsylvania Convention Center (Poster Board Number A310) (abstract). In addition, the next step in her project, 3D models using matrigels, will be presented at the same time by her undergraduate colleague Ayeisha Colón–Ortíz (abstract).

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
O. Hecmarie  Meléndez-Fernández

O. Hecmarie Meléndez-Fernández is a Ph.D. candidate in neuroscience at West Virginia University.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Predicting PROTAC properties

Predicting PROTAC properties

Dec. 8, 2022

Best of BMB 2022: Proteolysis-targeting chimeras bring together a drug target protein and a ubiquitin ligase to remove the target from the cell. But sometimes the process stalls out.

Cataloging itty-bitty proteins in large numbers

Cataloging itty-bitty proteins in large numbers

Dec. 7, 2022

Best of BMB 2022: Ribosome profiling has identified thousands of short protein-coding genes, many in unexpected parts of the genome. Research suggests some play important regulatory roles.

Giant, intricate structures

Giant, intricate structures

Dec. 6, 2022

Best of BMB 2022: In a “triumph of experimental structural biology,” multiple teams tackle the nuclear pore complex.

Evolutionary constraints on disordered proteins

Evolutionary constraints on disordered proteins

Dec. 5, 2022

Best of BMB 2022: “There’s evidence that there must be conservation of function — so how does this happen, if the sequence changes so much?”

COVID-19, preprints and journalists
Science Communication

COVID-19, preprints and journalists

Dec. 3, 2022

Researchers find that news stories often fail to mention when studies haven’t been peer reviewed.

From the journals: MCP
Journal News

From the journals: MCP

Dec. 2, 2022

Muscling in on a signaling pathway. Probing weaknesses in the T cell surface. Improving single-cell proteomics two ways. Read about papers on these topics recently published in the journal Molecular & Cellular Proteomics.